Streamlining Gene Therapy with AAVs
Gene therapies are enabling a rapid expansion in the scope of treatable disease. Adeno-associated viruses (AAVs) are particularly advantageous delivery vehicles for introducing functional genes to specific tissues or cells due to their simplicity, safety, and efficacy. A successful AAV discovery and development pipeline covers basic vector design, in vitro assays, in vivo biodistribution, immunogenicity, efficacy, and safety studies.
In this white paper, critical considerations for a successful AAV discovery and development pipeline are discussed. New technologies and design factors that increase both speed and safety are highlighted, including advanced self-silencing adenovirus technology which enables the safe, efficient creation of AAVs without contaminating adenoviruses.
White Paper_Streamlining Gene Therapy with AAVs
Related Content
Advances in the understanding of rare disease biology, coupled with innovative technology and therapeutic platforms, has led to progress in...
VIEW RESOURCENew modalities such as peptides, oligonucleotides, and cell and gene therapies have revolutionized healthcare industry innovation. To meet these evolving...
VIEW RESOURCE